There is a rapid growth in the number of people living with Alzheimer’s disease, and only around one in four people with the disease get diagnosed. It is estimated that there are approximately 44 ...

Patients with Alzheimer’s disease (AD) experience a slow progressive decline in memory and cognitive ability, among other symptoms, due to the spread of damage in the brain. Generally, the disease is ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Alzheimer’s News Today is a digital platform intended to provide the Alzheimer’s disease community with the most recent news and information on the disease, as well as first-hand community ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

When Lewis Hornby’s grandmother was rushed to the hospital in 2018, his family feared the worst. Pat Dickinson suffered from dementia, but in this instance it turned out that she was simply dehydrated ...

While there is no cure for Alzheimer’s disease, nor have any disease-modifying therapies been approved yet, there are several medications available by prescription to treat disease symptoms that ...

Mental health is an issue that continues to raise concern in the United States. According to an annual report by the nonprofit organization Mental Health America, incidences of anxiety and depression ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s application for the accelerated approval of its amyloid-clearing antibody donanemab for treating Alzheimer’s disease. An ...